The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 06, 2024
Filed:
Jul. 24, 2019
Applicant:
Accurus Biosciences, Inc., Richmond, CA (US);
Inventors:
Haishan Lin, Richmond, CA (US);
Richard Zhang, Richmond, CA (US);
Assignee:
ACCURUS BIOSCIENCES, INC., Richmond, CA (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 47/68 (2017.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
C07K 16/28 (2013.01); A61K 47/6849 (2017.08); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70578 (2013.01); G01N 33/6854 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01);
Abstract
Provided herein are novel anti-CLDN 18.2 antibodies and chimeric antigen receptors (CAR), cells or compositions comprising the same, vector or plasmid encoding anti-CLDN 18.2 CAR, anti-CLDN 18.2 antibody-drug conjugates (ADCs), bispecific antibodies containing anti-CLDN 18.2 antibodies, and methods for producing the same, or using the same for detecting or treating ovarian cancer or prostate cancer. Also provided herein are anti-CLDN 18.2 antibodies, compositions comprising the same, nucleic acid sequence encoding the same, and a kit for detecting CLDN 18.2.